ReviewMedical science monitor : international medical journal of experimental and clinical research2026
Indications for Dual Antiplatelet Therapy in Coil-Only Treatment of Ruptured Intracranial Aneurysms: A Narrative Review.
Review in Medical science monitor : international medical journal of experimental and clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This narrative review synthesizes published evidence regarding antiplatelet therapy strategies used during coil embolization of ruptured intracranial aneurysms, with particular emphasis on coil-only treatment and distinctions between coil-only and device-assisted procedures. The available literature suggests that antiplatelet therapy can reduce periprocedural thromboembolic complications, particularly in selected coil-only cases; however, evidence for consistent benefit in delayed cerebral ischemia, functional outcomes, or long-term recovery remains limited and heterogeneous. Importantly, findings from stent-assisted or flow-diverter-treated cohorts should not be directly extrapolated to coil-only procedures - antiplatelet therapy in device-assisted treatment is largely driven by implant-related thrombogenicity. The current evidence base is limited by retrospective study designs, single-center cohorts, heterogeneous treatment protocols, and inconsistent endpoint definitions. At present, no standardized antiplatelet regimen can be recommended for routine use in coil-only aneurysmal subarachnoid hemorrhage. Ongoing randomized studies, including the ASTOP trial, may help clarify the benefit-risk balance and determine whether a more evidence-based, procedure-specific antiplatelet strategy can be established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.